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Is crowdfunding a viable 
source of clinical trial 
research funding?
As public research grants for 
randomised controlled trials (RCTs) 
have diminished and become in-
creasingly competitive, researchers 
have to search for alternative funding 
sources. Crowdfunding, in which 
projects are funded directly from the 
public through the internet, might 
represent a potential source of RCT 
funding.1 However, whether or not 
crowdfunding campaigns for clinical 
RCTs are successful is unclear.
To explore the success of research 
crowdfunding campaigns,  we 
assessed the top online (based 
on site volume) English crowd-
funding websites:  Gofundme, 
Indiegogo, Kickstarter, Teespring, 
Patreon, YouCaring, CrowdRise, 
DonorsChoose, Kiva, and Giveforward. 
Additionally, we examined medical 
research crowdfunding websites: 
Experiment, Consano, Petridish, and 
Cancer Research UK. We (AS and 
JK) independently searched these 
crowdfunding websites using the 
following search terms: ”clinical 
study”, ”randomized clinical trial”, and 
”research”. We also independently 
established whether a campaign 
met our eligibility criteria of funding 
for a clinical RCT that was led by an 
academic or research institution. 
A consensus process to resolve 
disagreements was established. 
20 campaigns met our eligibility 
criteria (Cohen’s κ=0·88; appendix). 
Eight (62%) of 13 completed 
campaigns achieved their fundraising 
goals. Unsuccessful campaigns 
raised 1–6% of the funding sought. 
Five (63%) of eight campaigns that 
reached their funding goals were for 
pilot or phase 1 studies. 19 (95%) of 
20 campaigns used a ﬂ exible model 
(ie, researchers kept all the funds 
raised) compared with a ﬁ xed model 
(ie, researchers kept the money only 
if the target was met). The maximum 
funds raised were US$3 113 000 
(£2 000 000) for the Oncolytic Virus 
for Patients with Neuroendocrine 
Tumours study. Although details were 
restricted, most research projects 
seemed to have had some funding 
from other sources. 
Our research suggests that most 
crowdfunding campaign funding 
targets are achieved. Crowdfunding 
might represent an eﬀ ective option to 
rapidly raise research funds to do RCTs. 
Even unsuccessful campaigns were 
able to raise some funds, albeit a small 
percentage of their target goal. This 
strategy might be especially useful 
for pilot or phase 1 studies because 
funding from national public agencies 
is insuﬃ  cient. Further research with 
crowdfunding is needed to establish 
strategies that maximise the likelihood 
of success.
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later in life, geriatric medicine is 
not synonymous with palliative 
medicine, and curative (but also 
preventive) actions are often 
possible.4 Non-frail individuals 
make up a substantial proportion of 
people aged 70 years or older and 
their treatment results for diseases 
such as cardiovascular diseases and 
cancer do not differ from those 
who are younger. In pre-frail and 
frail individuals, good results are 
often obtainable with individualised 
treatment, but this is clearly an area 
where more research is needed.
If preventive actions at young 
ages are increasingly successful, 
we will also have healthier elderly 
people in the future than we do 
now; this notion is important for 
the extrapolation of Goal 3.4. In 
the meantime, we need geriatric 
medicine for the increasing number 
of people aged 70 years or older who 
have chronic disorders. The proper 
treatment of these elderly people is 
a human rights issue, but geriatric 
medicine is also effective to promote 
functionality and wellbeing, giving 
more life to years lived.
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Legal preparedness and 
Ebola vaccines
On Dec 9, 2014, US Secretary of Health 
and Human Services Sylvia Burwell 
issued a declaration1 under the US 
Public Readiness and Emergency 
Preparedness Act to provide immunity 
from legal claims in the USA related to 
manufacturing, testing, development, 
distribution, and administration of 
three candidate Ebola vaccines except 
in instances of wilful misconduct. 
Although progress in combating 
Ebola in west Africa has shifted 
public attention away from vaccine 
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development and deployment, we 
should not forget that the manage-
ment of legal liabilities related to 
vaccines has been an important 
subject of discussion between 
national governments, international 
organisations, vaccine manufacturers, 
and other parties who have been 
engaged in the worldwide response to 
the Ebola outbreak during the past year. 
On the basis of previous experience 
with other vaccines,2 it is reasonable 
to expect that administration of 
Ebola vaccines (or similar medical 
countermeasures responding to 
other public health emergencies 
in the future) will almost certainly 
result in at least some adverse 
events that will give rise to legal 
liabilities, for which it is not clear 
what the legal and ﬁ nancial process 
for claims against manufacturers, 
distributors, or providers might be. 
Individuals experiencing such adverse 
events, manufacturers, governments 
receiving vaccines (eg, Guinea, Liberia, 
and Sierra Leone in the context of 
Ebola in west Africa), governments 
supporting vaccine distribution 
outside of their borders (eg, the USA, 
the UK, and France in the case of 
Ebola), and populations benefiting 
from widespread vaccination all have 
a shared interest in recognising, 
understanding, and managing poten-
tial liability as eﬀ ectively as possible 
within the framework of a global 
public health response.
Legal immunities for innovators and 
manufacturers of vaccines, such as 
the Public Readiness and Emergency 
Preparedness declaration made by 
Secretary Burwell, can be part of the 
solution. However, the cost of injuries 
attributable to vaccines should not 
simply fall on target populations. To 
allow such a result to occur risks feeding 
the same doubts that have thwarted 
some vaccination eﬀ orts in low-income 
and middle-income countries across 
the world. Several options are available 
to the global public health community 
to address potential legal liabilities 
in various public health emergency 
scenarios, including situations such 
as the Ebola outbreak. Unlike many 
contingencies associated with future 
pandemics or similar global public 
health crises that are diﬃ  cult—if not 
impossible—to predict, creating an 
improved framework for management 
of legal liabilities is a preparation 
that all interested stakeholders can 
make before the next global health 
emergency occurs.
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Another step change for 
tobacco control in 
China?
In their Editorial about tobacco 
control in China (May 30, p 2122),1 
the Editors of The Lancet discussed the 
steps that the Chinese Government 
is taking to control tobacco, which 
includes the adjustment of China’s 
consumption tax on the wholesale 
price of cigarettes. Is increasing 
tobacco taxation really another step 
change for tobacco control in China? 
China is the world’s largest tobacco 
producer and manufacturer, and is 
also home to more than 300 million 
smokers who consume over one-third 
of the world’s cigarettes and another 
740 million people who are exposed 
to passive smoking. Tobacco use in 
China is causing a substantial rise 
in health hazards and economic 
burden, therefore comprehensive 
tobacco control is clearly needed. 
International experience and results of 
studies consistently show that raising 
taxes on tobacco is one of the most 
cost-eﬀ ective ways to reduce tobacco 
use.2 Hence, the WHO and relevant 
experts have repeatedly suggested 
that the Chinese Government should 
control tobacco use by sharply 
increasing tobacco taxes. However, for 
a long time, the government has been 
hesitating to use such strategies in its 
bid to reduce tobacco use for some 
well known reasons.3
The excise taxes on cigarettes in 
China have always been very low: in 
2011, taxes levied on the retail price of 
cigarettes were still far from reaching 
the 70% suggested by WHO. A tobacco 
consumption tax was introduced 
in 1994, and the tax rate increased 
slightly in 1998, 2001, and 2009. 
Furthermore, every time the tobacco 
tax rate increased, China’s tobacco 
industry subsequently increased their 
subsidies to cigarette manufacturers to 
oﬀ set the negative eﬀ ect. As a result, 
tobacco excise taxes could not be fully 
passed on to retail prices, and the retail 
prices barely changed. 
On May 7, 2015, the Chinese 
Ministry of Finance announced an 
increment in the consumption tax 
on wholesale cigarettes from 5% to 
11% and each cigarette would also be 
taxed ¥0·005.4 The next day, the State 
Tobacco Monopoly Administration 
announced a 6% increase in wholesale 
cigarette prices and recommended 
a 10% increase in the retail price 
of each pack of cigarettes.5 Unlike 
previous tobacco tax adjustments, this 
increase in tobacco taxes is passed on 
to retail prices, which was considered 
impossible when taking into account 
the unique relation between the 
tobacco industry and the Chinese 
Government. After May 10, 2015, 
we observed that cigarette prices 
had increased by about 10% in many 
tobacco stores. 
Most people who care about 
tobacco control welcome tobacco 
tax adjustment and regard it as 
another step for tobacco control in 
China after the announcement of a 
For the Global Adults Tobacco 
Survey China 2010 see http://
www.who.int/tobacco/
surveillance/survey/gats/en_
gats_china_report.pdf?ua=1
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